ROCKVILLE, Md., April 18, 2011 /PRNewswire-USNewswire/ -- Accelovance, a privately held clinical research company has been named the “Best Contract Research Organization (CRO)” for a third consecutive year. The World Vaccine Congress, held last week at the Gaylord National Hotel and Convention Center, Washington, D.C., hosted its annual Vaccine Industry Excellence (ViE) Awards to honor and generate recognition of the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry over the past 12 months.
“Recognition from our colleagues and clients at this level is truly an honor. I believe consistency in performance, value and partnership is what defines our company’s success,” said Stephen J. Trevisan, President and CEO.
The “Best CRO” category is designed to highlight the importance of contract research services within the vaccine industry; Accelovance has won the award three of the four years it has been a finalist. An international panel of judges evaluates category finalists on quality of work, range of services, strength of client relationships and performance.
“Quality and commitment are what define our organization,” remarked Lee Barsky, Vice President of CRO Services. “It is equally rewarding to see how our diverse service offering helps Sponsors maintain growth despite challenging times in the industry.”
Accelovance supports the business needs of biotech and small/mid pharma companies with cost-effective, flexible solutions that extend beyond traditional CRO services. Recently, the balanced perspective of study management and site operations positioned Accelovance to successfully rescue two Phase III therapeutic vaccine programs. Additionally, several Phase I vaccine studies in support of novel manufacturing or delivery methods are currently underway.
Headquartered in Rockville, Maryland, Accelovance has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies. Accelovance offers wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability, and quality assurance to vaccine programs. Additionally, the Company tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets a Sponsor’s needs. Accelovance has a 100% owned subsidiary providing CRO services in China. These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.
For more information, visit the company’s website at http://www.accelovance.com.
Media Contact:
Angie Wing
Phone: 240.238.4921
awing@accelovance.com
SOURCE Accelovance
